ClinicalTrials.gg
CompletedNCT02413346Updated Feb 1, 2019Results posted

A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris

A Phase 3 interventional study of Sarecycline in Acne Vulgaris, sponsored by Almirall, S.A.. Completed at 56 sites in United States. Open to participants aged 9 Years and older. Per ClinicalTrials.gov, last updated 2019-02-01.

Sponsored by Almirall, S.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
490
Allocation
Non-randomized
Ages
9 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 373 studies in Acne Vulgaris with a site in United States — 20 open to participants now, 29 under way, 2 of them phase 3. Acne Vulgaris · United States.

Enrollment
78th of 353
490 · median 78
Started
2015
with 24 others
Phase 3
76 of 373
1 open now
Registered
164th of 373
by date
Lead sponsor
8 of 373
Almirall, S.A.

Among the 373 studies in Acne Vulgaris with a site in United States, this one is the 78th largest by enrollment of the 353 interventional ones that give a count, is one of 25 that started in 2015, is one of 76 in phase 3, and was the 164th registered.

Acne Vulgaris

791 studies on the registry are indexed under Acne Vulgaris; 94 are open to participants now.

Browse Acne Vulgaris studies →

Open to participants now

20 of the 373 studies in Acne Vulgaris with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 47 Acne Vulgaris studies recruiting now, 17 (36%) set no upper age limit and 29 (62%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.

This study: 9 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 373 studies in Acne Vulgaris with a site in United States, or all of them as a file.
02

Study summary

Open-label study will evaluate the safety of an approximate 1.5 mg/kg/day dose of oral sarecycline in the long-term treatment of participants with moderate to severe facial acne vulgaris.

03

Conditions studied

  • Acne Vulgaris

Browse trials for

04

Who can participate

Ages eligible
9 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Successfully completed participation in Phase 3 study of sarecycline (SC1401 or SC1402)
  • Signed or assent form
  • Body weight between 33 kg and 136 kg, inclusive
  • Negative urine pregnancy test for females of
  • Agrees to use effective method of throughout study, if applicable.
  • Able to fulfill protocol requirements, indicated willingness to participate in study and agrees to all study procedures by providing written informed consent/assent and authorization to disclose (personal health information)

Exclusion criteria

Exclusion Criteria:

  • Currently participating in another clinical study, unless it is a pharmacokinetic sarecycline study and participation approved by medical monitor; has received medication (except sarecycline) within 30 days of enrollment.
  • Discontinued participation in a Phase 3 study with sarecycline for any reason
  • Had poor compliance wtih study requirements/study drug dosing in a Phase 3 study with sarecycline
  • Is receiving/planning to receive any systemic acne medication, systemic retinoids, systemic or any androgen/anti-androgenic therapy (eg, testosterone, spironolactone)
  • Is pregnant, lactating or planning a pregnancy during the study period
  • Has a significant intercurrent illness (including abnormality in clinical laboratory tests), psychiatric disorder, or other factors that, in the opinion of the Investigator or Medical Monitor, precludes participation in the study
  • Is judged by the Investigator to be unsuitable for any reason
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
490 participants (actual)

Study arms

  • Experimental
    Placebo/Sarecycline

    Participants received placebo-matching sarecyline in the double-blind lead-in study for up to 12 weeks; followed by, 1.5 milligram(mg)/kilogram(kg) sarecycline once daily (administered orally as 60 mg, 100 mg or 150 mg of sarecycline based on the participant's body weight) until adequate improvement in facial acne is obtained with re-initiation if acne recurs in this open-label study (Up to 40 weeks).

    Drug: Sarecycline

  • Experimental
    Sarecycline/Sarecycline

    Participants received sarecyline in the double-blind lead-in study for up to 12 weeks; followed by, 1.5 mg/kg sarecycline once daily (administered orally as 60 mg, 100 mg or 150 mg of sarecycline based on the participant's body weight) until adequate improvement in facial acne is obtained with re-initiation if acne recurs in this open-label study (Up to 40 weeks).

    Drug: Sarecycline

Interventions

  • Administered based on participant's body weight.

06

What researchers measure

Primary outcomes

  1. Number of Participants With at Least 1 Treatment-Emergent Adverse Event (TEAE)

    An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. A TEAE is an AE that occurs after the first dose of study drug.

    Time frame: Up to 40 Weeks

07

Results

Posted May 4, 2018

Participant flow

Long-term safety study for participants who were treated for moderate to severe facial acne vulgaris in the double-blind studies SC1401 \[NCT02320149\] or SC1402 \[NCT02322866\].

Participant flow — Overall Study
MilestonePlacebo/SarecyclineSarecycline/Sarecycline
Started236247
Completed177177
Not completed5970
Withdrew: Adverse event66
Withdrew: Withdrawal by subject3040
Withdrew: Lost to follow-up1721
Withdrew: Protocol violation20
Withdrew: Other miscellaneous reasons43

Outcome measures

PrimaryNumber of Participants With at Least 1 Treatment-Emergent Adverse Event (TEAE)

An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. A TEAE is an AE that occurs after the first dose of study drug.

Time frame:
Up to 40 Weeks
Reported as:
Number · participants
Number of Participants With at Least 1 Treatment-Emergent Adverse Event (TEAE)
participantsPlacebo/SarecyclineSarecycline/Sarecycline
Number of Participants With at Least 1 Treatment-Emergent Adverse Event (TEAE)9494

Adverse events

Collected over Signing of informed consent for this open-label study to end of study (Up to 40 Weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo/Sarecycline0/236 (0%)2/236 (0.8%)13/236 (5.5%)
Sarecycline/Sarecycline0/247 (0%)2/247 (0.8%)5/247 (2%)
Most frequent serious events
Most frequent serious events
EventPlacebo/SarecyclineSarecycline/Sarecycline
AnaemiaBlood and lymphatic system disorders1/2360/247
Peptic ulcerGastrointestinal disorders1/2360/247
HeadacheNervous system disorders1/2360/247
Abdominal painGastrointestinal disorders0/2361/247
DehydrationMetabolism and nutrition disorders0/2361/247
Most frequent other events
Most frequent other events
EventPlacebo/SarecyclineSarecycline/Sarecycline
NasopharyngitisInfections and infestations13/2365/247

Baseline characteristics

Safety Population included all participants among the screened population who were exposed to study treatment (sarecycline) in either the double-blind lead-in study or this open-label extension study.

Age, Customized
Age, Customized(participants)Placebo/SarecyclineSarecycline/SarecyclineTotal
≥9 and <12 years235
≥12 and <18 years138152290
≥18 years9692188
Sex: Female, Male
Sex: Female, Male(Participants)Placebo/SarecyclineSarecycline/SarecyclineTotal
Female122125247
Male114122236
08

Study locations

56 sites
  • Actavis Investigational Study Site #206
    Mobile, Alabama 36608, United States
  • Actavis Investigational Study Site #236
    Hot Springs, Arkansas 71913, United States
  • Actavis Investigational Study Site #245
    Carlsbad, California 92008, United States
  • Actavis Investigational Study Site #129
    Encino, California 91436, United States
  • Actavis Investigational Study Site #209
    Fremont, California 94538, United States
  • Actavis Investigational Study Site #147
    Sacramento, California 95819, United States
  • Actavis Investigational Study Site #150
    San Diego, California 92120, United States
  • Actavis Investigational Study Site #125
    San Diego, California 92123, United States
  • Actavis Investigational Study Site #204
    San Diego, California 92123, United States
  • Actavis Investigational Study Site #222
    Denver, Colorado 80220, United States
  • Actavis Investigational Study Site #148
    Wheat Ridge, Colorado 80033, United States
  • Actavis Investigational Study Site #226
    Clearwater, Florida 33761, United States
  • Actavis Investigational Study Site #238
    Jupiter, Florida 33458, United States
  • Actavis Investigational Study Site #249
    Miami, Florida 33142, United States
  • Actavis Investigational Study Site #145
    Miami, Florida 33175, United States
  • Actavis Investigational Study Site #211
    Miramar, Florida 33207, United States
  • Actavis Investigation Study Site # 140
    North Miami Beach, Florida 33162, United States
  • Actavis Investigational Study Site #151
    Orange, Florida 32073, United States
  • Actavis Investigational Study Site #203
    Tampa, Florida 33609, United States
  • Actavis Investigational Study Site #242
    Snellville, Georgia 30078, United States
  • Actavis Investigational Study Site #124
    Boise, Idaho 83704, United States
  • Actavis Investigational Study Site #106
    Chicago, Illinois 60611, United States
  • Actavis Investigational Study Site #113
    South Bend, Indiana 46617, United States
  • Actavis Investigational Study Site #213
    Louisville, Kentucky 40202, United States
  • Actavis Investigational Study Site #217
    Rockville, Maryland 20850, United States
  • Actavis Investigational Study Site #251
    Clarkston, Michigan 48346, United States
  • Actavis Investigational Study Site #235
    Clinton Township, Michigan 48038, United States
  • Actavis Investigational Study Site #227
    Fort Gratiot, Michigan 48059, United States
  • Actavis Investigational Study Site #111
    Warren, Michigan 48088, United States
  • Actavis Investigational Study Site #221
    Fridley, Minnesota 55432, United States
  • Actavis Investigational Study Site #231
    Omaha, Nebraska 68144, United States
  • Actavis Investigational Study Site #146
    New York, New York 10016, United States
  • Actavis Investigational Study Site #208
    New York, New York 10155, United States
  • Actavis Investigational Study Site #240
    Rochester, New York 14623, United States
  • Actavis Investigational Study Site #230
    Stony Brook, New York 11790, United States
  • Actavis Investigational Study Site #229
    Raleigh, North Carolina 27612, United States
  • Actavis Investigational Study Site #149
    Gresham, Oregon 97030, United States
  • Actavis Investigational Study Site #257
    Philadelphia, Pennsylvania 19103, United States
  • Actavis Investigational Study Site #225
    Goodlettsville, Tennessee 37072, United States
  • Actavis Investigational Study Site #128
    Knoxville, Tennessee 37917, United States
  • Actavis Investigational Study Site #216
    Knoxville, Tennessee 37922, United States
  • Actavis Investigational Study Site #109
    Nashville, Tennessee 37215, United States
  • Actavis Investigational Study Site #223
    Arlington, Texas 76011, United States
  • Actavis Investigational Study Site #252
    Arlington, Texas 76011, United States
  • Actavis Investigational Study Site #220
    College Station, Texas 77845, United States
  • Actavis Investigational Study Site #104
    Dallas, Texas 75234, United States
  • Actavis Investigational Study Site #142
    Houston, Texas 77004, United States
  • Actavis Investigational Study Site #105
    Houston, Texas 77056, United States
  • Actavis Investigational Study Site #201
    Katy, Texas 77494, United States
  • Actavis Investigational Study Site #223
    Pflugerville, Texas 78660, United States
  • Actavis Investigational Study Site #101
    Plano, Texas 75093, United States
  • Actavis Investigational Study Site #207
    San Antonio, Texas 78218, United States
  • Actavis Investigational Study Site #212
    West Jordan, Utah 84088, United States
  • Actavis Investigational Study Site #244
    Norfolk, Virginia 23507, United States
  • Actavis Investigational Study Site #144
    Spokane, Washington 99202, United States
  • Actavis Investigational Study Site #233
    Walla Walla, Washington 99362, United States
09

References and documents

Publications

  • Pariser DM, Green LJ, Lain EL, Schmitz C, Chinigo AS, McNamee B, Berk DR. Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris: Results from a Phase III, Multicenter, Open-Label Study and a Phase I Phototoxicity Study. J Clin Aesthet Dermatol. 2019 Nov;12(11):E53-E62. Epub 2019 Nov 1. PubMed 32038757 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2015 to primary completion in Aug 2016, 17 months.

Results were first posted in May 2018, 1 year 8 months after primary completion.

Of 53 industry-sponsored phase 3 interventional studies under Acne Vulgaris, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 17. This study's 17 months is above that.

Counting every sponsor, half of 62 studies reached it within 13 months; a quarter within 10 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2015
First posted
Apr 9, 2015
StartActual
Mar 20, 2015
Primary completionActual
Aug 26, 2016
CompletionActual
Aug 26, 2016
Results first posted
May 4, 2018
Last update
Feb 1, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02413346
Lead sponsor
Almirall, S.A.
Collaborators
Allergan
Responsible party
Sponsor
First posted
Apr 9, 2015
Start date
Mar 20, 2015
Primary completion
Aug 26, 2016
Completion
Aug 26, 2016
Results posted
May 4, 2018
Last update
Feb 1, 2019

Study contacts

David Berk, MD
study director · Allergan, plc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sarecycline

Start the discussion